liquidia-new-logo.png
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
07 mai 2024 08h00 HE | Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024.
LIQUIDIA_Logo.jpg
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
18 mai 2020 07h15 HE | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
11 mai 2020 16h01 HE | Liquidia Technologies, Inc.
Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...
LIQUIDIA_Logo.jpg
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
07 janv. 2019 07h00 HE | Liquidia Technologies, Inc.
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
LIQUIDIA_Logo.jpg
Liquidia Technologies Provides Leadership Update
27 nov. 2018 16h45 HE | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
14 nov. 2018 16h30 HE | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
14 nov. 2018 08h00 HE | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies to Present at Jefferies London Healthcare Conference
09 nov. 2018 08h00 HE | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
LIQUIDIA_Logo.jpg
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
31 oct. 2018 07h00 HE | Liquidia Technologies, Inc.
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...
LIQUIDIA_Logo.jpg
Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018
23 oct. 2018 08h00 HE | Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development...